NeuroSense schedules FDA meeting for ALS drug trial By Investing.com
CAMBRIDGE, Mass. - NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a biotech agency specializing in neurodegenerative illness therapies, has secured a Kind ...
Monday, February 3, 2025
Tag: FDA
Biogen’s kidney transplant rejection candidate gets FDA breakthrough designation
peterschreiber.media Biogen (NASDAQ:BIIB) has obtained U.S. FDA breakthrough remedy designation for felzartamab, its candidate being developed to deal with antibody-mediated ...
Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment
Supply: Recursion Prescribed drugsAI drug pioneer Recursion Prescribed drugs stated Wednesday that one in all its experimental remedies hit a ...
RECOMMENDED
My Conversation with Bank of America’s Savita Subramanian – Meb Faber Research – Stock Market and Investing Blog
Savita Subramanian got here on the podcast final week and didn't disappoint! Savita is the Head of US Fairness Technique...
Copyright © 2024 PWC.